Unicycive Therapeutics, Inc. SEC filings UNCY

Unicycive Therapeutics, Inc. has 307 filings in SEC EDGAR's recent list, going back to Mar 4, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (officer or director change, other events). The company's fiscal year ends on December 31.

Unicycive Therapeutics, Inc. SEC filings
Form Description Filed Period
S-3 Shelf registration Jun 5, 2026 —
S-8 Employee stock plan registration May 6, 2026 —
424B5 Prospectus supplement Nov 14, 2025 —
424B5 Prospectus supplement Jun 13, 2025 —
S-8 Employee stock plan registration Apr 1, 2025 —
S-3 Shelf registration Nov 13, 2024 —
POS AM Post effective amendment no. 1 to form s-3 Nov 13, 2024 —
424B3 Prospectus Jul 16, 2024 —
S-3 Shelf registration Jul 5, 2024 —
S-8 Employee stock plan registration Dec 8, 2023 —
S-3 Shelf registration Jul 13, 2023 —
S-3 Shelf registration Aug 16, 2022 —
S-8 Employee stock plan registration Sep 10, 2021 —
424B4 Prospectus Jul 14, 2021 —
S-1/A Amended registration statement Jul 12, 2021 —
S-1/A Amended registration statement Jul 12, 2021 —
S-1/A Amended registration statement Jun 30, 2021 —
S-1/A Amended registration statement Jun 21, 2021 —
S-1/A Amended registration statement Jun 7, 2021 —
S-1 Registration statement May 21, 2021 —

Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
UNCY (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Mountain View, CA
SEC filer status
, Emerging growth company
SEC CIK
1766140
Former names
Unicycive Therapeutics, Inc. (until Oct 29, 2026)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.